Q-omics provides the consensus-scored HNRNPA1P57 profile across patient tissues and cancer cell-line models. HNRNPA1P57 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P57 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, HNRNPA1P57 RNA expression shows 7,246 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, and PDAC as cancer lineages where HNRNPA1P57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P57 survival associations across molecular data types. HNRNPA1P57 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P57 RNA expression–survival associations across cancer types. High HNRNPA1P57 expression shows unfavorable associations in STAD and LUSC, but favorable associations in BRCA, OV, THYM and THCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for HNRNPA1P57 RNA expression.
This table summarizes HNRNPA1P57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P57 shows lower tumor expression in UCEC and higher tumor expression in BRCA, THCA, LIHC, PRAD and READ. The BRCA box plot shows higher HNRNPA1P57 RNA expression in tumor versus normal tissue (log2 FC = +1.679, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P57 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P57 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
